Atropos Health Inc.

Atropos Health is a healthcare technology company specializing in the generation of high-quality, personalized real-world evidence (RWE) from clinical data. Its core mission is to inform every treatment decision with personalized RWE, thereby addressing the significant evidence gap prevalent in healthcare. Founded in 2019/2020 as a spin-out from Stanford University's "Green Button" technology, the company maintains its headquarters in New York, NY.

The company offers a comprehensive suite of solutions, including GENEVA OS™, an operating system designed for rapid healthcare evidence, and ChatRWD™, a generative AI application that significantly accelerates the production of publication-grade RWE. Additional offerings include Alexandria®, a vast repository of medical evidence, and specialized on-demand clinical informatics consultations. Atropos Health serves a diverse clientele, including health systems, academic institutions, pharmacy organizations, and life science companies, providing essential tools for clinical decision-making, research, policy development, and drug development.

Under the leadership of CEO and Co-founder Dr. Brigham Hyde, Atropos Health successfully raised $33 million in Series B funding in May 2024, contributing to a total funding exceeding $50 million. The company has garnered industry recognition, being named a 2026 Fierce 15 Company and included in the 2026 New York Digital Health 100. Recent strategic advancements include the integration of its AI-driven Atropos Evidence™ Agent into Microsoft Teams and a collaboration with Novartis aimed at streamlining rare disease diagnosis. Atropos Health is positioned as a leader in leveraging artificial intelligence and real-world data to deliver rapid, credible, and transparent evidence across the healthcare ecosystem.